OncoMatch/Clinical Trials/NCT05066412
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
Is NCT05066412 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for hematologic malignancy.
To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Excluded: PTPRC aberrant expression
Donor aberrant CD45RA expression due to a polymorphism in CD45 gene
Prior therapy
Must have received: haploidentical stem cell transplant after reduced-intensity conditioning
Patients who received a stem cell graft from a haploidentical donor after RIC for hematologic malignancies
Cannot have received: second allogeneic transplant
Second allogeneic transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify